Abcellera Biologics Inc
NASDAQ:ABCL

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
NASDAQ:ABCL
Watchlist
Price: 2.76 USD 1.47% Market Closed
Market Cap: 815.2m USD
Have any thoughts about
Abcellera Biologics Inc?
Write Note

Abcellera Biologics Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Abcellera Biologics Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Abcellera Biologics Inc
NASDAQ:ABCL
Additional Paid In Capital
$121.1m
CAGR 3-Years
174%
CAGR 5-Years
141%
CAGR 10-Years
N/A
Arch Biopartners Inc
XTSX:ARCH
Additional Paid In Capital
CA$7.5m
CAGR 3-Years
17%
CAGR 5-Years
22%
CAGR 10-Years
53%
Replicel Life Sciences Inc
XTSX:RP
Additional Paid In Capital
CA$5.7m
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
9%
Innovotech Inc
XTSX:IOT
Additional Paid In Capital
CA$1.6m
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
11%
No Stocks Found

Abcellera Biologics Inc
Glance View

Market Cap
802.7m USD
Industry
Life Sciences Tools & Services

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.

ABCL Intrinsic Value
1.67 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Abcellera Biologics Inc's Additional Paid In Capital?
Additional Paid In Capital
121.1m USD

Based on the financial report for Dec 31, 2023, Abcellera Biologics Inc's Additional Paid In Capital amounts to 121.1m USD.

What is Abcellera Biologics Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
141%

Over the last year, the Additional Paid In Capital growth was 63%. The average annual Additional Paid In Capital growth rates for Abcellera Biologics Inc have been 174% over the past three years , 141% over the past five years .

Back to Top